JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Silvan Tuerkcan has reiterated a Market Outperform rating on Terns Pharma (NASDAQ:TERN) and maintained a $17 price target.
July 26, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Terns Pharma's stock rating has been reiterated as Market Outperform by JMP Securities, with a maintained price target of $17.
The reiteration of a Market Outperform rating by JMP Securities indicates a positive outlook for Terns Pharma. The maintained price target of $17 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100